In Brief: Oxymedyca
This article was originally published in The Gray Sheet
Oxymedyca: Company's biomedical division begins limited marketing of its HIV-RIT in vitro rapid enzyme immunoassay screening assay for antibodies to HIV-1 and HIV-2 in serum, plasma or whole blood. The qualitative, initial screening assay, which has both sensitivity and specificity of 99.9%, takes 15 minutes to complete...
You may also be interested in...
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.